Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Mutations in neurofibromin, a Ras GTPase-activating protein, lead to the tumor predisposition syndrome neurofibromatosis type 1. Here, we report that cells lacking neurofibromin exhibit enhanced glycolysis and decreased respiration in a Ras/ERK-dependent way. In the mitochondrial matrix of neurofibromin-deficient cells, a fraction of active ERK1/2 associates with succinate dehydrogenase (SDH) and TRAP1, a chaperone that promotes the accumulation of the oncometabolite succinate by inhibiting SDH. ERK1/2 enhances both formation of this multimeric complex and SDH inhibition. ERK1/2 kinase activity is favored by the interaction with TRAP1, and TRAP1 is, in turn, phosphorylated in an ERK1/2-dependent way. TRAP1 silencing or mutagenesis at the serine residues targeted by ERK1/2 abrogates tumorigenicity, a phenotype that is reverted by addition of a cell-permeable succinate analog. Our findings reveal that Ras/ERK signaling controls the metabolic changes orchestrated by TRAP1 that have a key role in tumor growth and are a promising target for anti-neoplastic strategies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2016.12.056DOI Listing

Publication Analysis

Top Keywords

trap1
6
absence neurofibromin
4
neurofibromin induces
4
induces oncogenic
4
oncogenic metabolic
4
metabolic switch
4
switch mitochondrial
4
mitochondrial erk-mediated
4
erk-mediated phosphorylation
4
phosphorylation chaperone
4

Similar Publications

TRAP1 and its therapeutic potential.

Bioorg Med Chem Lett

September 2025

Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, United States. Electronic address:

The mitochondrial Hsp90 isoform, Tumor Necrosis Factor Receptor Associated Protein 1 (TRAP1), is central to the pathogenesis of disease states that include cancer, ischemic retinopathy, and diabetic kidney disease among others. TRAP1 contributes to these diseases through the regulation of mitochondrial metabolism, apoptosis, oxidative stress, cell signaling and angiogenesis through interactions with client proteins. Numerous TRAP1-selective inhibitors have been developed to limit the toxicities associated with Hsp90 pan-inhibition, while leveraging the therapeutic benefits of TRAP1 inhibition.

View Article and Find Full Text PDF

Heat shock proteins have been increasingly identified in RNA-interactomes, suggesting potential roles beyond their canonical functions. Among those, the cancer-linked chaperone TRAP1 has been mainly characterized for its regulatory role on respiratory complex activity and protein synthesis, while its specific function as an RNA-binding protein (RBP) remains unclear. In this study, we confirmed the RNA-binding activity of TRAP1 in living cells using both protein- and RNA-centric approaches and demonstrated that multiple TRAP1 regions cooperate in such binding.

View Article and Find Full Text PDF

Background: Metabolic adaptations can sustain the pro-neoplastic functions exerted by macrophages in the tumor microenvironment. Malignant peripheral nerve sheath tumors (MPNSTs), aggressive and incurable sarcomas that develop either sporadically or in the context of the genetic syndrome Neurofibromatosis type 1, are highly infiltrated by macrophages, whose contribution to MPNST growth remains poorly characterized. Here, we analyze the role played by the molecular chaperone TRAP1, a regulator of mitochondrial metabolic pathways, in shaping the pro-tumoral activity of macrophages associated to MPNST cells.

View Article and Find Full Text PDF

TRAP1 promotes self-renewal and tumorigenicity of glioblastoma stem cells by inhibiting Notch1 ubiquitination.

Biochem Biophys Res Commun

August 2025

Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. Electronic address:

Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system and is classified as Grade IV in the World Health Organization (WHO)'s brain tumor categorization. Even with standard treatment protocols, the median overall survival of newly diagnosed GBM patients is only 14.6 months.

View Article and Find Full Text PDF

Colorectal cancer (CRC) is a prevalent malignant neoplasm on a global scale, with tumor heterogeneity driving therapeutic resistance and poor prognosis. RNA-binding proteins (RBPs), which are involved in regulating post-transcriptional processes, are becoming more recognized for their involvement in the advancement of cancer. This research conducted a thorough examination of the prognostic and functional significance of RBP-related gene sets (RBPGs) in CRC by utilizing transcriptomic data from the cancer genome atlas (TCGA).

View Article and Find Full Text PDF